PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-5.92%
Revenue decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
-0.56%
Cost reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive advantage potential.
-17.46%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-12.27%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-0.60%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
3.07%
G&A change of 3.07% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
7.60%
Marketing expense change of 7.60% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-1.49%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
2.64%
Operating expenses change of 2.64% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
0.85%
Total costs change of 0.85% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
-29.59%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-2.20%
D&A reduction while Drug Manufacturers - Specialty & Generic median is 0.12%. Seth Klarman would investigate efficiency.
-144.55%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-5663.80%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-31.73%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-40.02%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
42.37%
Other expenses change of 42.37% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify control.
-25.20%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-33.09%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-262.43%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
6.32%
Income change of 6.32% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
0.42%
Margin change of 0.42% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
16.67%
EPS change of 16.67% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
9.09%
Diluted EPS change of 9.09% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
8.22%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.01%. Jim Chanos would check for issues.
6.33%
Diluted share change of 6.33% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.